363 Resources in

Medshorts

By month
Neuro
2 Min Read
15 Apr

Efficacy and safety of DaxibotulinumtoxinA in cervical dystonia

A recent study has shown that DaxibotulinumtoxinA (DAXI) is an effective and well-tolerated treatment for cervical dystonia (CD) when administered at doses of 125U and 250U. The study’s findings were published in the journal, Neurology.

ASPEN-1 was a phase 3 clinical trial that involved participants aged 18-80 years with moderate-to-severe CD. The study was randomized, double-blind, and placebo-controlled, with 301 participants receiving single-dose intramuscular DAXI 125U (n=125), 250U (n=130), or placebo (n=46). The change from baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score averaged across weeks 4 and 6 was the primary end point of this study, while duration of effect, Clinical and Patient Global Impression of Change (CGIC), (PGIC),TWSTRS subscale scores, and safety outcomes were the key secondary end points included.

DAXI 125U and 250U exhibited a substantial increase in the mean TWSTRS total score when compared to the placebo group (least squares mean [standard error] difference vs placebo: DAXI 125U, -8.5; DAXI 250U, -6.6). The median duration of effect with DAXI 125U was 24.0 weeks, while with DAXI 250U it was 20.3 weeks. Notable improvements were also seen in CGIC and PGIC responder rates, as well as TWSTRS subscales.

Therefore, it can be inferred that DAXI, administered at 125U and 250U dosages, could serve as an effective, long-acting, safe, and well-tolerated therapy for CD.

Efficacy and safety of DaxibotulinumtoxinA in cervical dystonia

A recent study has shown that DaxibotulinumtoxinA (DAXI) is an effective and well-tolerated treatment for cervical dystonia (CD) when administered at doses of 125U and 250U. The study’s findings were published in the journal, Neurology.

ASPEN-1 was a phase 3 clinical trial that involved participants aged 18-80 years with moderate-to-severe CD. The study was randomized, double-blind, and placebo-controlled, with 301 participants receiving single-dose intramuscular DAXI 125U (n=125), 250U (n=130), or placebo (n=46). The change from baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score averaged across weeks 4 and 6 was the primary end point of this study, while duration of effect, Clinical and Patient Global Impression of Change (CGIC), (PGIC),TWSTRS subscale scores, and safety outcomes were the key secondary end points included.

DAXI 125U and 250U exhibited a substantial increase in the mean TWSTRS total score when compared to the placebo group (least squares mean [standard error] difference vs placebo: DAXI 125U, -8.5; DAXI 250U, -6.6). The median duration of effect with DAXI 125U was 24.0 weeks, while with DAXI 250U it was 20.3 weeks. Notable improvements were also seen in CGIC and PGIC responder rates, as well as TWSTRS subscales.

Therefore, it can be inferred that DAXI, administered at 125U and 250U dosages, could serve as an effective, long-acting, safe, and well-tolerated therapy for CD.

Neuro
2 Min Read
15 Apr

Efficacy and safety of DaxibotulinumtoxinA in cervical dystonia

A recent study has shown that DaxibotulinumtoxinA (DAXI) is an effective and well-tolerated treatment for cervical dystonia (CD) when administered at doses of 125U and 250U. The study’s findings were published in the journal, Neurology.

ASPEN-1 was a phase 3 clinical trial that involved participants aged 18-80 years with moderate-to-severe CD. The study was randomized, double-blind, and placebo-controlled, with 301 participants receiving single-dose intramuscular DAXI 125U (n=125), 250U (n=130), or placebo (n=46). The change from baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score averaged across weeks 4 and 6 was the primary end point of this study, while duration of effect, Clinical and Patient Global Impression of Change (CGIC), (PGIC),TWSTRS subscale scores, and safety outcomes were the key secondary end points included.

DAXI 125U and 250U exhibited a substantial increase in the mean TWSTRS total score when compared to the placebo group (least squares mean [standard error] difference vs placebo: DAXI 125U, -8.5; DAXI 250U, -6.6). The median duration of effect with DAXI 125U was 24.0 weeks, while with DAXI 250U it was 20.3 weeks. Notable improvements were also seen in CGIC and PGIC responder rates, as well as TWSTRS subscales.

Therefore, it can be inferred that DAXI, administered at 125U and 250U dosages, could serve as an effective, long-acting, safe, and well-tolerated therapy for CD.

button
Oncology
2 Min Read
10 Apr

Efficacy and safety of mirvetuximab soravtansine-gynx in the treatment of platinum-resistant ovarian cancer

A recent study found that mirvetuximab soravtansine-gynx (MIRV) targeting folate receptor α (FRα) showed a significant benefit over chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. This study’s results were published in The New England Journal of Medicine.

This phase 3, global, confirmatory, open-label, randomized, controlled trial included 453 participants who were randomized in a 1:1 ratio to receive 6 mg per kilogram of adjusted ideal body weight of MIRV every 3 weeks (N=227) or chemotherapy that included paclitaxel, pegylated liposomal doxorubicin, or topotecan (n=226). The primary end point of the study was progression-free survival. The key secondary analytic end points of the study included overall survival, objective response, and participant-reported outcomes.

It was observed that the median progression-free survival with MIRV and chemotherapy was 5.62 months and 3.98 months, respectively. An objective response occurred in 42.3% and 15.9% of the participants in the MIRV and chemotherapy groups, respectively. The overall survival was found to be significantly longer with MIRV than with chemotherapy (16.46 months vs. 12.75 months). Similarly, during the treatment period, fewer adverse events of grade 3 or above, SAEs (serious adverse events) of any grade, and events leading to discontinuation, occurred with MIRV compared to chemotherapy.

Based on the above results, it can be concluded that treatment with MIRV may show a significant benefit with respect to progression-free survival, overall survival, and objective response among participants with platinum-resistant, FRα-positive ovarian cancer. Thus, it may be safe and efficacious for use.

Efficacy and safety of mirvetuximab soravtansine-gynx in the treatment of platinum-resistant ovarian cancer

A recent study found that mirvetuximab soravtansine-gynx (MIRV) targeting folate receptor α (FRα) showed a significant benefit over chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. This study’s results were published in The New England Journal of Medicine.

This phase 3, global, confirmatory, open-label, randomized, controlled trial included 453 participants who were randomized in a 1:1 ratio to receive 6 mg per kilogram of adjusted ideal body weight of MIRV every 3 weeks (N=227) or chemotherapy that included paclitaxel, pegylated liposomal doxorubicin, or topotecan (n=226). The primary end point of the study was progression-free survival. The key secondary analytic end points of the study included overall survival, objective response, and participant-reported outcomes.

It was observed that the median progression-free survival with MIRV and chemotherapy was 5.62 months and 3.98 months, respectively. An objective response occurred in 42.3% and 15.9% of the participants in the MIRV and chemotherapy groups, respectively. The overall survival was found to be significantly longer with MIRV than with chemotherapy (16.46 months vs. 12.75 months). Similarly, during the treatment period, fewer adverse events of grade 3 or above, SAEs (serious adverse events) of any grade, and events leading to discontinuation, occurred with MIRV compared to chemotherapy.

Based on the above results, it can be concluded that treatment with MIRV may show a significant benefit with respect to progression-free survival, overall survival, and objective response among participants with platinum-resistant, FRα-positive ovarian cancer. Thus, it may be safe and efficacious for use.

Oncology
2 Min Read
10 Apr

Efficacy and safety of mirvetuximab soravtansine-gynx in the treatment of platinum-resistant ovarian cancer

A recent study found that mirvetuximab soravtansine-gynx (MIRV) targeting folate receptor α (FRα) showed a significant benefit over chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. This study’s results were published in The New England Journal of Medicine.

This phase 3, global, confirmatory, open-label, randomized, controlled trial included 453 participants who were randomized in a 1:1 ratio to receive 6 mg per kilogram of adjusted ideal body weight of MIRV every 3 weeks (N=227) or chemotherapy that included paclitaxel, pegylated liposomal doxorubicin, or topotecan (n=226). The primary end point of the study was progression-free survival. The key secondary analytic end points of the study included overall survival, objective response, and participant-reported outcomes.

It was observed that the median progression-free survival with MIRV and chemotherapy was 5.62 months and 3.98 months, respectively. An objective response occurred in 42.3% and 15.9% of the participants in the MIRV and chemotherapy groups, respectively. The overall survival was found to be significantly longer with MIRV than with chemotherapy (16.46 months vs. 12.75 months). Similarly, during the treatment period, fewer adverse events of grade 3 or above, SAEs (serious adverse events) of any grade, and events leading to discontinuation, occurred with MIRV compared to chemotherapy.

Based on the above results, it can be concluded that treatment with MIRV may show a significant benefit with respect to progression-free survival, overall survival, and objective response among participants with platinum-resistant, FRα-positive ovarian cancer. Thus, it may be safe and efficacious for use.

button
Nephrology
2 Min Read
08 Apr

Aranesp more efficient in achieving target hemoglobin than Eprex, with less dose changes and minor complications

A recent study suggests that Aranesp Q weekly or every 2 weeks is more efficient than Eprex in achieving target Hb in hemodialysis (HD) patients. This study was published in the journal, International Urology and Nephrology.

This prospective, randomized, open-labeled study conducted for 24 weeks included 139 patients who were undergoing HD for >3 months and were >18 years of age, and on Eprex for >3 months. The patients were randomized into Aranesp group (A; n=72) and Eprex group (B; n=67). Patients in A group who were on Eprex Q TIW or BIW were converted to Aranesp Q weekly, by using the conversion factor of 200:1 and those on Eprex Q weekly were converted to Aranesp Q 2 weeks. On the other hand, B group patients continued on Eprex treatment. The primary end points of the study were percentage of patients achieving target Hb, number of dose changes in each group, and hemoglobin variability.

It was seen that target Hb was achieved in 64.8 % of the Aranesp and 59.7 % in the Eprex group. Mean number of dose changes was 1.3 and 1.9 in the Aranesp and Eprex groups, respectively. Also, the Hb variability was less frequent in the Aranesp group. Thus, it can be concluded that with less dose changes and minor vascular access complications, Aranesp Q weekly or every 2 weeks may be more efficient than Eprex in achieving target Hb in HD patients.

Aranesp more efficient in achieving target hemoglobin than Eprex, with less dose changes and minor complications

A recent study suggests that Aranesp Q weekly or every 2 weeks is more efficient than Eprex in achieving target Hb in hemodialysis (HD) patients. This study was published in the journal, International Urology and Nephrology.

This prospective, randomized, open-labeled study conducted for 24 weeks included 139 patients who were undergoing HD for >3 months and were >18 years of age, and on Eprex for >3 months. The patients were randomized into Aranesp group (A; n=72) and Eprex group (B; n=67). Patients in A group who were on Eprex Q TIW or BIW were converted to Aranesp Q weekly, by using the conversion factor of 200:1 and those on Eprex Q weekly were converted to Aranesp Q 2 weeks. On the other hand, B group patients continued on Eprex treatment. The primary end points of the study were percentage of patients achieving target Hb, number of dose changes in each group, and hemoglobin variability.

It was seen that target Hb was achieved in 64.8 % of the Aranesp and 59.7 % in the Eprex group. Mean number of dose changes was 1.3 and 1.9 in the Aranesp and Eprex groups, respectively. Also, the Hb variability was less frequent in the Aranesp group. Thus, it can be concluded that with less dose changes and minor vascular access complications, Aranesp Q weekly or every 2 weeks may be more efficient than Eprex in achieving target Hb in HD patients.

Nephrology
2 Min Read
08 Apr

Aranesp more efficient in achieving target hemoglobin than Eprex, with less dose changes and minor complications

A recent study suggests that Aranesp Q weekly or every 2 weeks is more efficient than Eprex in achieving target Hb in hemodialysis (HD) patients. This study was published in the journal, International Urology and Nephrology.

This prospective, randomized, open-labeled study conducted for 24 weeks included 139 patients who were undergoing HD for >3 months and were >18 years of age, and on Eprex for >3 months. The patients were randomized into Aranesp group (A; n=72) and Eprex group (B; n=67). Patients in A group who were on Eprex Q TIW or BIW were converted to Aranesp Q weekly, by using the conversion factor of 200:1 and those on Eprex Q weekly were converted to Aranesp Q 2 weeks. On the other hand, B group patients continued on Eprex treatment. The primary end points of the study were percentage of patients achieving target Hb, number of dose changes in each group, and hemoglobin variability.

It was seen that target Hb was achieved in 64.8 % of the Aranesp and 59.7 % in the Eprex group. Mean number of dose changes was 1.3 and 1.9 in the Aranesp and Eprex groups, respectively. Also, the Hb variability was less frequent in the Aranesp group. Thus, it can be concluded that with less dose changes and minor vascular access complications, Aranesp Q weekly or every 2 weeks may be more efficient than Eprex in achieving target Hb in HD patients.

button
Derma
2 Min Read
05 Apr

Adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel effective in preventing worsening of atrophic acne scars

According to a recent study, maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris. This study was published in the Journal of Dermatology.

This randomized study included 126 patients, who were randomized to receive adapalene/benzoyl peroxide (n = 40), benzoyl peroxide (n = 44), and control (without maintenance treatment drugs (n = 42). Among these patients, 111 individuals completed a trial lasting for 24 weeks. The primary endpoint and one of the secondary endpoints of the study were treatment success rate (the percentage of patients in whom the number of inflammatory lesions was maintained at ≤10) and the rate of change in the number of atrophic scars, respectively.

At week 24, the treatment success rate was 89.2% in the adapalene/benzoyl peroxide group, 87.5% in the benzoyl peroxide group, and 47.4% in the control group. The treatment success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups compared to the control group. Additionally, the rate of change in the number of atrophic scars showed significant improvement from the baseline in the adapalene/benzoyl peroxide and benzoyl peroxide groups.

Based on these findings, it may be suggested that maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris.

Adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel effective in preventing worsening of atrophic acne scars

According to a recent study, maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris. This study was published in the Journal of Dermatology.

This randomized study included 126 patients, who were randomized to receive adapalene/benzoyl peroxide (n = 40), benzoyl peroxide (n = 44), and control (without maintenance treatment drugs (n = 42). Among these patients, 111 individuals completed a trial lasting for 24 weeks. The primary endpoint and one of the secondary endpoints of the study were treatment success rate (the percentage of patients in whom the number of inflammatory lesions was maintained at ≤10) and the rate of change in the number of atrophic scars, respectively.

At week 24, the treatment success rate was 89.2% in the adapalene/benzoyl peroxide group, 87.5% in the benzoyl peroxide group, and 47.4% in the control group. The treatment success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups compared to the control group. Additionally, the rate of change in the number of atrophic scars showed significant improvement from the baseline in the adapalene/benzoyl peroxide and benzoyl peroxide groups.

Based on these findings, it may be suggested that maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris.

Derma
2 Min Read
05 Apr

Adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel effective in preventing worsening of atrophic acne scars

According to a recent study, maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris. This study was published in the Journal of Dermatology.

This randomized study included 126 patients, who were randomized to receive adapalene/benzoyl peroxide (n = 40), benzoyl peroxide (n = 44), and control (without maintenance treatment drugs (n = 42). Among these patients, 111 individuals completed a trial lasting for 24 weeks. The primary endpoint and one of the secondary endpoints of the study were treatment success rate (the percentage of patients in whom the number of inflammatory lesions was maintained at ≤10) and the rate of change in the number of atrophic scars, respectively.

At week 24, the treatment success rate was 89.2% in the adapalene/benzoyl peroxide group, 87.5% in the benzoyl peroxide group, and 47.4% in the control group. The treatment success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups compared to the control group. Additionally, the rate of change in the number of atrophic scars showed significant improvement from the baseline in the adapalene/benzoyl peroxide and benzoyl peroxide groups.

Based on these findings, it may be suggested that maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris.

button
Oncology
2 Min Read
04 Apr

Effect of amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC

A recent study suggests that amivantamab plus chemotherapy with and without lazertinib improved progression-free survival (PFS) and intracranial PFS in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). This study’s results were published in the Annals of Oncology.

The MARIPOSA-2 study was a phase III trial that included 657 patients with EGFR-mutated locally advanced or metastatic NSCLC. After disease progression on osimertinib, these patients were randomized in a 2:2:1 ratio to receive either amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. Progression-free survival of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy were the dual primary endpoints of the study.

At the end of the study, it was found that for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, the PFS was significantly longer compared to chemotherapy alone (median of 6.3 and 8.3 versus 4.2 months, respectively). Investigator assessment revealed consistent PFS outcomes for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy (median of 8.2 and 8.3 versus 4.2 months, respectively). The objective response rate was found to be significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively). Similarly, median intracranial PFS for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy was 12.5 and 12.8 versus 8.3 months, respectively.

Based on the above results, it can be concluded that there may be improved PFS and intracranial PFS with amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy.

Effect of amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC

A recent study suggests that amivantamab plus chemotherapy with and without lazertinib improved progression-free survival (PFS) and intracranial PFS in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). This study’s results were published in the Annals of Oncology.

The MARIPOSA-2 study was a phase III trial that included 657 patients with EGFR-mutated locally advanced or metastatic NSCLC. After disease progression on osimertinib, these patients were randomized in a 2:2:1 ratio to receive either amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. Progression-free survival of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy were the dual primary endpoints of the study.

At the end of the study, it was found that for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, the PFS was significantly longer compared to chemotherapy alone (median of 6.3 and 8.3 versus 4.2 months, respectively). Investigator assessment revealed consistent PFS outcomes for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy (median of 8.2 and 8.3 versus 4.2 months, respectively). The objective response rate was found to be significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively). Similarly, median intracranial PFS for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy was 12.5 and 12.8 versus 8.3 months, respectively.

Based on the above results, it can be concluded that there may be improved PFS and intracranial PFS with amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy.

Oncology
2 Min Read
04 Apr

Effect of amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC

A recent study suggests that amivantamab plus chemotherapy with and without lazertinib improved progression-free survival (PFS) and intracranial PFS in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). This study’s results were published in the Annals of Oncology.

The MARIPOSA-2 study was a phase III trial that included 657 patients with EGFR-mutated locally advanced or metastatic NSCLC. After disease progression on osimertinib, these patients were randomized in a 2:2:1 ratio to receive either amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. Progression-free survival of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy were the dual primary endpoints of the study.

At the end of the study, it was found that for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, the PFS was significantly longer compared to chemotherapy alone (median of 6.3 and 8.3 versus 4.2 months, respectively). Investigator assessment revealed consistent PFS outcomes for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy (median of 8.2 and 8.3 versus 4.2 months, respectively). The objective response rate was found to be significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively). Similarly, median intracranial PFS for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy was 12.5 and 12.8 versus 8.3 months, respectively.

Based on the above results, it can be concluded that there may be improved PFS and intracranial PFS with amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy.

button
Cardiac
2 Min Read
03 Apr

Digitoxin dosing found safe in heart failure with reduced ejection fraction

A recent study suggests that use of digitoxin is simple and safe in heart failure with reduced ejection fraction (HFrEF). The study results were published in the journal, Clinical research in Cardiology.

The DIGIT-HF was a randomized, double-blind trial that enrolled 317 patients who were administered with a dose of digitoxin at 0.07 mg once daily (o.d.). At week 6, after serum levels were determined, the digitoxin dose was either left unchanged or reduced to 0.05 mg o.d. For females with age ≥ 75 years, eGFR < 50 ml/min/1.73 m2, and body mass index (BMI) < 27 kg/m2 each, one point for the digitoxin dosing score was assigned. The need for dose reduction was determined with a score of ≥ 1 that indicated sensitivity/specificity of 81.6%/49.7%, respectively.

On analysis of the validation data that included 64 randomized patients, it was found that digitoxin yielded sensitivity/specificity of 87.5%/37.5%, respectively. Thus, for patients with HFrEF, the treatment dosage of digitoxin should be started at 0.05 mg o.d. in either female sex with age ≥ 75 years, eGFR < 50 ml/min/1.73m2, or BMI < 27 kg/m2. For other patients, the safe dosage of digitoxin may be 0.07 mg o.d. Hence, digitoxin dosing may be simple and safe in patients with HFrEF.

Digitoxin dosing found safe in heart failure with reduced ejection fraction

A recent study suggests that use of digitoxin is simple and safe in heart failure with reduced ejection fraction (HFrEF). The study results were published in the journal, Clinical research in Cardiology.

The DIGIT-HF was a randomized, double-blind trial that enrolled 317 patients who were administered with a dose of digitoxin at 0.07 mg once daily (o.d.). At week 6, after serum levels were determined, the digitoxin dose was either left unchanged or reduced to 0.05 mg o.d. For females with age ≥ 75 years, eGFR < 50 ml/min/1.73 m2, and body mass index (BMI) < 27 kg/m2 each, one point for the digitoxin dosing score was assigned. The need for dose reduction was determined with a score of ≥ 1 that indicated sensitivity/specificity of 81.6%/49.7%, respectively.

On analysis of the validation data that included 64 randomized patients, it was found that digitoxin yielded sensitivity/specificity of 87.5%/37.5%, respectively. Thus, for patients with HFrEF, the treatment dosage of digitoxin should be started at 0.05 mg o.d. in either female sex with age ≥ 75 years, eGFR < 50 ml/min/1.73m2, or BMI < 27 kg/m2. For other patients, the safe dosage of digitoxin may be 0.07 mg o.d. Hence, digitoxin dosing may be simple and safe in patients with HFrEF.

Cardiac
2 Min Read
03 Apr

Digitoxin dosing found safe in heart failure with reduced ejection fraction

A recent study suggests that use of digitoxin is simple and safe in heart failure with reduced ejection fraction (HFrEF). The study results were published in the journal, Clinical research in Cardiology.

The DIGIT-HF was a randomized, double-blind trial that enrolled 317 patients who were administered with a dose of digitoxin at 0.07 mg once daily (o.d.). At week 6, after serum levels were determined, the digitoxin dose was either left unchanged or reduced to 0.05 mg o.d. For females with age ≥ 75 years, eGFR < 50 ml/min/1.73 m2, and body mass index (BMI) < 27 kg/m2 each, one point for the digitoxin dosing score was assigned. The need for dose reduction was determined with a score of ≥ 1 that indicated sensitivity/specificity of 81.6%/49.7%, respectively.

On analysis of the validation data that included 64 randomized patients, it was found that digitoxin yielded sensitivity/specificity of 87.5%/37.5%, respectively. Thus, for patients with HFrEF, the treatment dosage of digitoxin should be started at 0.05 mg o.d. in either female sex with age ≥ 75 years, eGFR < 50 ml/min/1.73m2, or BMI < 27 kg/m2. For other patients, the safe dosage of digitoxin may be 0.07 mg o.d. Hence, digitoxin dosing may be simple and safe in patients with HFrEF.

button
Nephrology
2 Min Read
02 Apr

Darbepoetin-α effective in anemia correction, improving cardiovascular performance than epoetin-α

A recent study suggests that darbepoetin-α is effective in correcting anemia and improving cardiovascular performance in chronic kidney disease (CKD) patients compared to epoetin-α. This study was published in the journal, Cardiorenal Medicine.

This single-centre, retrospective, observational study included 100 stage IV CKD patients. They were given erythropoiesis-stimulating agents (ESA) i.e. 20 μg darbepoetin-α weekly and 2,000 IU epoetin-α thrice weekly in a 1:300 conversion ratio. This study evaluated the cardiovascular outcomes in the two groups and every 3 months, haemoglobin (Hb), C-reactive protein, hematocrit, basal echocardiograms and pro-brain natriuretic peptide (BNP) were monitored.

At the end of the study, it was observed that darbepoetin-α was significantly more effective than epoetin-α in increasing Hb levels after 3, 6, 9, and 12 months. Compared to 70% of patients treated with epoetin-α, the optimal Hb target level was reached after one year of treatment with darbepoetin-α. Cardiovascular performance after darbepoetin-α treatment significantly improved at the 6- and 12-month follow-ups.

Based on the above results, it can be concluded that darbepoetin-α may appear to be effective in correcting anemia and improving cardiovascular performance in CKD patients compared to epoetin-α.

Darbepoetin-α effective in anemia correction, improving cardiovascular performance than epoetin-α

A recent study suggests that darbepoetin-α is effective in correcting anemia and improving cardiovascular performance in chronic kidney disease (CKD) patients compared to epoetin-α. This study was published in the journal, Cardiorenal Medicine.

This single-centre, retrospective, observational study included 100 stage IV CKD patients. They were given erythropoiesis-stimulating agents (ESA) i.e. 20 μg darbepoetin-α weekly and 2,000 IU epoetin-α thrice weekly in a 1:300 conversion ratio. This study evaluated the cardiovascular outcomes in the two groups and every 3 months, haemoglobin (Hb), C-reactive protein, hematocrit, basal echocardiograms and pro-brain natriuretic peptide (BNP) were monitored.

At the end of the study, it was observed that darbepoetin-α was significantly more effective than epoetin-α in increasing Hb levels after 3, 6, 9, and 12 months. Compared to 70% of patients treated with epoetin-α, the optimal Hb target level was reached after one year of treatment with darbepoetin-α. Cardiovascular performance after darbepoetin-α treatment significantly improved at the 6- and 12-month follow-ups.

Based on the above results, it can be concluded that darbepoetin-α may appear to be effective in correcting anemia and improving cardiovascular performance in CKD patients compared to epoetin-α.

Nephrology
2 Min Read
02 Apr

Darbepoetin-α effective in anemia correction, improving cardiovascular performance than epoetin-α

A recent study suggests that darbepoetin-α is effective in correcting anemia and improving cardiovascular performance in chronic kidney disease (CKD) patients compared to epoetin-α. This study was published in the journal, Cardiorenal Medicine.

This single-centre, retrospective, observational study included 100 stage IV CKD patients. They were given erythropoiesis-stimulating agents (ESA) i.e. 20 μg darbepoetin-α weekly and 2,000 IU epoetin-α thrice weekly in a 1:300 conversion ratio. This study evaluated the cardiovascular outcomes in the two groups and every 3 months, haemoglobin (Hb), C-reactive protein, hematocrit, basal echocardiograms and pro-brain natriuretic peptide (BNP) were monitored.

At the end of the study, it was observed that darbepoetin-α was significantly more effective than epoetin-α in increasing Hb levels after 3, 6, 9, and 12 months. Compared to 70% of patients treated with epoetin-α, the optimal Hb target level was reached after one year of treatment with darbepoetin-α. Cardiovascular performance after darbepoetin-α treatment significantly improved at the 6- and 12-month follow-ups.

Based on the above results, it can be concluded that darbepoetin-α may appear to be effective in correcting anemia and improving cardiovascular performance in CKD patients compared to epoetin-α.

button
Derma
2 Min Read
01 Apr

Low-molecular-weight collagen peptides supplementation promotes healthy skin

A recent study demonstrated that supplementation of low-molecular-weight collagen peptides has been found to effectively enhance various properties of human skin, including wrinkling, hydration, elasticity, and whitening. The findings of this study were published in the journal of cosmetic dermatology.

This randomized, double-blinded, placebo-controlled study included 100 healthy adult participants, who were randomly assigned to receive either low-molecular-weight collagen peptides or a placebo. The skin's parameters such as wrinkles, elasticity, hydration, and whitening (melanin and erythema indexes) were assessed at the beginning and after 4, 8, and 12 weeks.

Compared to the placebo group, the test group exhibited significant improvements in various skin measurements such as average skin roughness, maximum peak-to-valley values, maximum peak height of the wrinkle, and average maximum height of the wrinkle. Additionally, parameters related to skin elasticity, including overall elasticity, net elasticity, and biological elasticity, showed significant improvements in the test group compared to the placebo group at week 12 week. Furthermore, the test group demonstrated more significant changes in skin hydration and whitening parameters compared to the placebo group. Importantly, no adverse events related to the test product were reported by any of the participants.

Thus, it can be concluded that low-molecular-weight collagen peptides may enhance the appearance of human skin by reducing wrinkles, increasing hydration, improving elasticity, and promoting a brighter complexion.

Low-molecular-weight collagen peptides supplementation promotes healthy skin

A recent study demonstrated that supplementation of low-molecular-weight collagen peptides has been found to effectively enhance various properties of human skin, including wrinkling, hydration, elasticity, and whitening. The findings of this study were published in the journal of cosmetic dermatology.

This randomized, double-blinded, placebo-controlled study included 100 healthy adult participants, who were randomly assigned to receive either low-molecular-weight collagen peptides or a placebo. The skin's parameters such as wrinkles, elasticity, hydration, and whitening (melanin and erythema indexes) were assessed at the beginning and after 4, 8, and 12 weeks.

Compared to the placebo group, the test group exhibited significant improvements in various skin measurements such as average skin roughness, maximum peak-to-valley values, maximum peak height of the wrinkle, and average maximum height of the wrinkle. Additionally, parameters related to skin elasticity, including overall elasticity, net elasticity, and biological elasticity, showed significant improvements in the test group compared to the placebo group at week 12 week. Furthermore, the test group demonstrated more significant changes in skin hydration and whitening parameters compared to the placebo group. Importantly, no adverse events related to the test product were reported by any of the participants.

Thus, it can be concluded that low-molecular-weight collagen peptides may enhance the appearance of human skin by reducing wrinkles, increasing hydration, improving elasticity, and promoting a brighter complexion.

Derma
2 Min Read
01 Apr

Low-molecular-weight collagen peptides supplementation promotes healthy skin

A recent study demonstrated that supplementation of low-molecular-weight collagen peptides has been found to effectively enhance various properties of human skin, including wrinkling, hydration, elasticity, and whitening. The findings of this study were published in the journal of cosmetic dermatology.

This randomized, double-blinded, placebo-controlled study included 100 healthy adult participants, who were randomly assigned to receive either low-molecular-weight collagen peptides or a placebo. The skin's parameters such as wrinkles, elasticity, hydration, and whitening (melanin and erythema indexes) were assessed at the beginning and after 4, 8, and 12 weeks.

Compared to the placebo group, the test group exhibited significant improvements in various skin measurements such as average skin roughness, maximum peak-to-valley values, maximum peak height of the wrinkle, and average maximum height of the wrinkle. Additionally, parameters related to skin elasticity, including overall elasticity, net elasticity, and biological elasticity, showed significant improvements in the test group compared to the placebo group at week 12 week. Furthermore, the test group demonstrated more significant changes in skin hydration and whitening parameters compared to the placebo group. Importantly, no adverse events related to the test product were reported by any of the participants.

Thus, it can be concluded that low-molecular-weight collagen peptides may enhance the appearance of human skin by reducing wrinkles, increasing hydration, improving elasticity, and promoting a brighter complexion.

button
1519 Resources in

Videos

View all
410 Resources in

Webinars

View all
1 Resources in

Courses

View all